Advertisement

Topics

Janssen's Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

05:46 EST 19 Feb 2018 | Pharmafile

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able to generate high skin clearance rates in patients with moderate to severe plaque psoriasis when administered as a long-term treatment.

read more

Original Article: Janssen's Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

NEXT ARTICLE

More From BioPortfolio on "Janssen's Tremfya shows long-term efficacy in moderate to severe plaque psoriasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...